Aztiq Pharma Partners Files Alvotech 13D/A Amendment

TL;DR

Aztiq Pharma Partners updated its Alvotech stake filing on 7/3/24.

AI Summary

Aztiq Pharma Partners S.a r.l. filed an amendment (No. 2) to its Schedule 13D on July 3, 2024, regarding its holdings in Alvotech. The filing indicates a change in the date as of which information is reported to July 1, 2024. Aztiq Pharma Partners S.a r.l. is based in Luxembourg and has a business phone number of +352 691 211 663.

Why It Matters

This filing updates significant ownership information for Alvotech, which could influence investor perception and trading activity.

Risk Assessment

Risk Level: low — The filing is an amendment to a previous filing and does not appear to introduce new or significantly altered risks.

Key Players & Entities

• Aztiq Pharma Partners S.a r.l. (company) — Filing entity
• Alvotech (company) — Subject company
• Danny Major (person) — Authorized contact
• July 1, 2024 (date) — Date as of change
• July 3, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.01 — er) Ordinary Shares, nominal value of $0.01 per share (Title of Class of Securitie
• $10.00 — bondholders at the conversion price of $10.00 per Ordinary Share on the conversion da

Filing Documents

• c109281_sch13da.htm (SC 13D/A) — 63KB
• c109281_ex99-2.htm (EX-99.2) — 8KB
• 0000930413-24-002002.txt ( ) — 72KB

of the Statement is hereby amended and restated as follows

Item 2 of the Statement is hereby amended and restated as follows: (a) This Statement is being jointly filed by Aztiq Pharma Partners S.à r.l. (“APP”), Aztiq Fund I SCSp (“Aztiq Fund”), Floki GP S.à r.l. (“Floki GP”), and ATP Holdings ehf. (“ATP” and, together with APP, Aztiq Fund, and Floki GP, the “Reporting Persons”), pursuant to Rule 13d-1(k) promulgated by the Securities and Exchange Commission (the “SEC”) pursuant to Section 13 of the Securities Exchange Act of 1934, as amended. The Managers of APP are: Danny Major, German citizen; Marc Lefebvre, Belgian citizen, Robert Wessman, Icelandic citizen; Johann Johannsson, Icelandic citizen; and Arni Hardarson, Icelandic citizen. APP is a wholly-owned subsidiary of Aztiq Fund. Investment and voting decisions at Aztiq Fund are made by its general partner, Floki GP. Each of Danny Major, Marc Lefebvre, Robert Wessman, Johann Johannsson and Arni Hardarson is a member of the board of directors of Floki GP, entitled to participate in investment and voting decisions with respect to the shares held by APP. Investment and voting decisions at ATP are made by its board of directors. Each of Robert Wessman, Johann Johannsson and Arni Hardarson is a member of the board of directors of ATP, entitled to participate in investment and voting decisions with respect to the shares held by ATP. (b) The business address of APP is 5, rue Heienhaff, L-1736 Senningerberg, Grand-Duchy of Luxembourg. The business address of Aztiq Fund and Floki GP is 4, rue Robert Stumper, L-2557 Luxembourg, Grand-Duchy of Luxembourg. The business address of ATP is Smaratorg 3, 201 Kopavogur, Iceland. (c) A present principal business of APP is to hold the securities of the Issuer, as described in this Statement. The present principal business of Aztiq Fund is to hold the securities of APP. The present principal business of Floki GP is to hold the securities of Aztiq Fun

of the Statement is amended by adding the following

Item 3 of the Statement is amended by adding the following: Bondholder Warrants On November 16, 2022, the Issuer and bondholders, including ATP, amended and restated certain terms and conditions of existing senior bonds and the Issuer issued new senior bonds. Pursuant to the terms of the amended bonds, the Issuer issued warrants to the bondholders on December 31, 2022 (the “Bondholder Warrants”). Each Bondholder Warrant entitles the holder, upon exercise, to receive one Ordinary Share, at the exercise price of $0.01 per share. ATP received 17,571 Bondholder Warrants in this transaction. As of the date hereof, ATP has not exercised the Bondholder Warrants, which are immediately exercisable. Conversion of Alvotech Convertible Bond : ATP exercised its right to convert the tranche A convertible bond instrument, dated 20 December 2022, between Alvotech as the issuer and the bondholders at the conversion price of $10.00 per Ordinary Share on the conversion date of June 30, 2024. Pursuant to the conversion, ATP received 2,587,089 Ordinary Shares on July 1, 2024. Item 4. Purpose of the Transaction.

of the Statement is amended by adding the following

Item 4 of the Statement is amended by adding the following: The information contained above in Item 3 of this Statement is incorporated herein by reference. Item 5. Interest in Securities of the Issuer.

of the Original Schedule 13D is hereby amended and restated

Item 5 of the Original Schedule 13D is hereby amended and restated as follows: (a) APP directly owns 101,147,803 Ordinary Shares. Aztiq Fund and Floki GP are deemed to beneficially own the 101,147,803 Ordinary Shares owned directly by APP. ATP directly owns 2,587,089 Ordinary Shares and 17,571 Bondholder Warrants. ATP disclaims beneficial ownership of the 101,147,803 Ordinary Shares held by APP. APP, Aztiq Fund and Floki GP disclaim beneficial ownership of the 2,587,089 Ordinary Shares and 17,571 Bondholder Warrants held by ATP. The beneficial ownership calculation is based upon 301,944,470 Ordinary Shares outstanding as of July 1, 2024, as stated in the Issuer’s Form 6-K filed on July 1, 2024. (b) APP, Aztiq Fund and Floki GP have shared voting and dispositive power over 101,147,803 Ordinary Shares, and sole voting and dispositive power over zero Ordinary Shares. ATP has sole voting and dispositive power over 2,604,660 Ordinary Shares (including 17,571 Ordinary Shares underlying the Bondholder Warrants), and shared voting and dispositive power over zero Ordinary Shares. (c) Item 3 sets forth all transactions with respect to the Issuer’s Ordinary Shares effective since the most recent amendment to this Schedule 13D. (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the Ordinary Shares beneficially owned by any of the Reporting Persons. (e) Not applicable. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

of the Statement is amended by adding the following

Item 6 of the Statement is amended by adding the following: The information set forth in Items 3 and 4 of this Statement is incorporated herein by reference. Item 7. Materials to be Filed as Exhibits. Exhibit 99.1 - December 2022 Convertible Bond Instrument (Tranche A) by and between Alvotech and the Bondholders named therein, dated December 20, 2022 (incorporated by reference to Exhibit 2.9 to the Form 20-F filed by the Issuer on March 1, 2023). Exhibit 99.2 - Joint Filing Agreement among the Reporting Persons, dated July 3, 2024. SIGNATURE After reasonable inquiry and to the best of each of the Reporting Person’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: July 3, 2024 Aztiq Pharma Partners S.à r.l. By: /s/ Danny Major Name: Danny Major Title: Manager By: /s/ Robert Wessman Name: Robert Wessman Title: Manager Aztiq Fund I SCSp, represented by its general partner, Floki GP S.à r.l. By: /s/ Danny Major Name: Danny Major Title: Manager By: /s/ Robert Wessman Name: Robert Wessman Title: Manager Floki GP S.à r.l. By: /s/ Danny Major Name: Danny Major Title: Manager By: /s/ Robert Wessman Name: Robert Wessman Title: Manager ATP Holdings ehf. By: /s/ Arni Hardarson Name: Arni Hardarson Title: Director By: /s/ Robert Wessman Name: Robert Wessman Title: Director [Signature Page to Schedule 13D/A]

View Full Filing

View this SC 13D/A filing on SEC EDGAR